Publications by authors named "Abundio Balgos"
Background: Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.
Research Design And Methods: Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivated vaccine (COVILO®) in the United Arab Emirates.
Article Synopsis
- ReCOV is a recombinant protein vaccine designed to provide broad protection against various SARS-CoV-2 variants, with studies conducted in New Zealand and the Philippines during phases I and II.
- The studies were randomized, double-blind, placebo-controlled trials involving healthy adults who received two doses of the vaccine 21 days apart, focusing on safety and immunogenicity outcomes.
- Results showed that while the ReCOV group experienced a higher incidence of mild to moderate adverse events in phase I, both groups had similar rates in phase II; the vaccine produced robust neutralizing antibodies against the virus, peaking 14 days after the second dose.